Claims for Patent: 7,825,133

Summary for Patent: 7,825,133

Title:	Derivatives of pyridone and the use of them
Abstract:	The present invention provides N-substituted-2(1H) pyridones or the pharmaceutical acceptable salts thereof, and the pharmaceutical preparations containing the compounds. The compounds of the present invention can be used to treat various fibrotic diseases effectively, e.g., hepatic fibrosis.
Inventor(s):	Yi; Xianghui (Shanghai, CN)
Assignee:	Shanghai Genomics, Inc. (Shanghai, CN)
Application Number:	10/579,288
Patent Claims:	1. A pharmaceutical composition comprising: (a) a therapeutically-effective amount of the compound of formula I or a pharmaceutically acceptable salts thereof, ##STR00009## wherein R.sub.1 is methyl, and R.sub.2 is hydroxyl; and (b) a pharmaceutically-acceptable excipient. 2. The pharmaceutical composition of claim 1, wherein R.sub.1 is methyl at position 5, and R.sub.2 is hydroxyl at position 4. 3. The pharmaceutical composition of claim 1, wherein the composition comprises 0.01-99% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight. 4. The pharmaceutical composition of claim 1, wherein composition is formulated as a tablet, capsule, ampule or pill. 5. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for oral, intravenous, intramuscular or subcutaneous administration. 6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for oral administration. 7. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for external administration. 8. The pharmaceutical composition of claim 1, wherein the composition is formulated as an ointment, gel, or drug-containing rubber cement. 9. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for parenteral administration. 10. The pharmaceutical composition of claim 1, wherein the composition comprises 0.1-90% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight. 11. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for slow release. 12. The pharmaceutical composition of claim 1, wherein the excipient is starch, lactin, dicalcium phosphate, microcrystalline cellulose, sucrose, white bole or combinations thereof. 13. The pharmaceutical composition of claim 1, wherein the excipient is sterile water, polyethylene glycol, a nonionic surfactant, edible oil or combinations thereof. 14. The pharmaceutical composition of claim 1, further comprising an adjuvant. 15. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for administration in 2-4 separated dosages per day. 16. The pharmaceutical composition of claim 1, further comprising a flavoring agent, colorant, preservative, antioxidant, or combinations thereof. 17. The pharmaceutical composition of claim 1, further comprising vitamin E, vitamin C, butylated hydroxytoluene (BHT), butylated hydroxy anisole (BHA) or combinations thereof.

Details for Patent 7,825,133

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-22